Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
Shubham Atal, Zeenat Fatima, Sakshi Singh, Balakrishnan Sadasivam, Rajnish Joshi
Topics & Concepts
MedicineDapagliflozinTolerabilityIntensive care medicineType 2 Diabetes MellitusDiabetes mellitusDrugType 2 diabetesPopulationClinical trialMedical prescriptionInternal medicineAdverse effectPharmacologyEndocrinologyEnvironmental healthDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer